Downregulation of Sef, an Inhibitor of Receptor Tyrosine Kinase Signaling, Is Common to a Variety of Human Carcinomas

Oncogene - United Kingdom
doi 10.1038/sj.onc.1210424
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The Human Sef-A Isoform Utilizes Different Mechanisms to Regulate Receptor Tyrosine Kinase Signaling Pathways and Subsequent Cell Fate

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2006English

Insulin-Like Growth Factor-I Receptor Blockade by a Specific Tyrosine Kinase Inhibitor for Human Gastrointestinal Carcinomas

Molecular Cancer Therapeutics
Cancer ResearchOncology
2008English

The Pim-1 Protein Kinase Is an Important Regulator of MET Receptor Tyrosine Kinase Levels and Signaling

Molecular and Cellular Biology
Cell BiologyMolecular Biology
2014English

Metastatic Adamantinoma Responds to Treatment With Receptor Tyrosine Kinase Inhibitor

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2010English

A Phosphoproteomic Analysis of the ErbB2 Receptor Tyrosine Kinase Signaling Pathways

English

Ror2 Receptor Requires Tyrosine Kinase Activity to Mediate Wnt5A Signaling

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2009English

The Selectivity of Receptor Tyrosine Kinase Signaling Is Controlled by a Secondary SH2 Domain Binding Site

Cell
BiochemistryGeneticsMolecular Biology
2009English

Preclinical Overview of Sorafenib, a Multikinase Inhibitor That Targets Both Raf and VEGF and PDGF Receptor Tyrosine Kinase Signaling

Molecular Cancer Therapeutics
Cancer ResearchOncology
2008English

Inhibition of Angiogenesis by Erbstatin, an Inhibitor of Tyrosine Kinase.

Journal of Antibiotics
Drug DiscoveryPharmacology
1993English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy